A MULTICENTER, RANDOMIZED PHASE-II STUDY OF RITUXIMAB (CHIMERIC ANTI-CD20 MAB) AT 2 DOSAGES IN PATIENTS WITH RELAPSED OR REFRACTORY INTERMEDIATE OR HIGH-GRADE NHL (IHG-NHL) OR IN ELDERLY PATIENTS IN FIRST-LINETHERAPY

COIFFIER B KETTERER N HAIOUN C REYES F DIEHL V TILLY H MA D JOHNSON P LISTER A HIDDEMANN G CROWTHER D CAPDEVILLE R

B. Coiffier et al., A MULTICENTER, RANDOMIZED PHASE-II STUDY OF RITUXIMAB (CHIMERIC ANTI-CD20 MAB) AT 2 DOSAGES IN PATIENTS WITH RELAPSED OR REFRACTORY INTERMEDIATE OR HIGH-GRADE NHL (IHG-NHL) OR IN ELDERLY PATIENTS IN FIRST-LINETHERAPY, Blood, 90(10), 1997, pp. 2271-2271

NO

Hematology

Blood → ACNP

00064971

90

10

1997

1

1

2271 - 2271

ISI

0006-4971(1997)90:10<2271:AMRPSO>2.0.ZU;2-F